REDWOOD CITY, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from four studies at the 31st Annual San Antonio Breast Cancer Symposium, taking place December 10-14, 2008, at the Henry B. Gonzalez Convention Center. Two of the studies analyze Oncotype DX(R), the company's multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit as well as the likelihood of recurrence for women with early-stage breast cancer.
Following are details for each embargoed session (all times are Central Standard Time):
-- Thursday, December 11, 2008, 4 p.m. - 4:15 p.m. Abstract #25 Oral presentation (General Session 2): "GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer" Presenter: Joseph Sparano, M.D., Montefiore-Einstein Cancer Center, New York Location: Exhibit Hall D -- Friday, December 12, 2008, 7 a.m. - 9 a.m. Abstract #2066 Poster presentation (Poster Session II: Prognosis and Response Predictions: Biomarkers -- Methods): "Quantitative gene expression analysis using Oncotype DX in ductal carcinoma in situ that is adjacent to invasive ductal carcinoma" Presenter: Rick Baehner, M.D., Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco Location: Exhibit Hall B -- Friday, December 12, 2008, 5 p.m. - 7 p.m. Abstract #3049 Poster presentation (Poster Session III: Tumor Cell and Molecular Biology: Hormonal Factors and Receptors): "Associations between estrogen receptor (ER) Alpha expression levels and ER genotypes" Presenter: Daniel Hayes, M.D., University of Michigan Health System, Ann Arbor Location: Exhibit Hall B -- Saturday, December 13, 2008, 10 a.m. - 10:15 a.m. Abstract #53 Oral presentation (General Session 5): "Risk of distant recurrence using Oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study" Presenter: Mitch Dowsett, Ph.D., Royal Marsden Hospital, London Location: Exhibit Hall D
About Oncotype DX(R)
Oncotype DX is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Additionally, the test report provides quantitative scores for certain individual genes. Oncotype DX has been extensively evaluated in eleven clinical studies involving more than 4,000 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, 7,500 physicians have ordered more than 75,000 tests, and both Medicare and private health plans covering approximately 90 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements or policy decisions. Both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.
About Genomic Health
Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(R), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
|SOURCE Genomic Health, Inc.|
Copyright©2008 PR Newswire.
All rights reserved